208 related articles for article (PubMed ID: 6975654)
1. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
2. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
[TBL] [Abstract][Full Text] [Related]
4. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG
Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
Blatt J; Venner PM; Riccardi R; Cohen LF; Gangji D; Glazer RI; Poplack DG
J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
[No Abstract] [Full Text] [Related]
8. Clinical pharmacology of deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
[TBL] [Abstract][Full Text] [Related]
9. Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Matsumoto SS; Yu AL; Bleeker LC; Bakay B; Kung FH; Nyhan WL
Blood; 1982 Nov; 60(5):1096-102. PubMed ID: 6289941
[TBL] [Abstract][Full Text] [Related]
10. 2'-Deoxycoformycin-induced hemolysis in the mouse.
Spremulli E; Crabtree GW; Dexter DL; Diamond I; Calabresi P
J Natl Cancer Inst; 1982 Jun; 68(6):1011-4. PubMed ID: 6979651
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
[TBL] [Abstract][Full Text] [Related]
12. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
Kefford RF; Fox RM
Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
14. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
15. Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2'-deoxycoformycin in vivo and in vitro.
Begleiter A; Glazer RI; Israels LG; Pugh L; Johnston JB
Cancer Res; 1987 May; 47(9):2498-503. PubMed ID: 3494509
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.
Mitchell BS; Koller CA; Heyn R
Blood; 1980 Sep; 56(3):556-9. PubMed ID: 6967747
[TBL] [Abstract][Full Text] [Related]
17. Deoxycoformycin: neurological toxicity.
Major PP; Agarwal RP; Kufe DW
Cancer Chemother Pharmacol; 1981; 5(3):193-6. PubMed ID: 6975188
[TBL] [Abstract][Full Text] [Related]
18. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
Hallam LJ; Van der Weyden MB; Ackland SP; Bagnara AS; Whiteside MG
Scand J Haematol; 1984 Jan; 32(1):55-64. PubMed ID: 6607510
[TBL] [Abstract][Full Text] [Related]
19. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
[TBL] [Abstract][Full Text] [Related]
20. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]